Mark S. Wilke, PhD Partner Patent Agent

Speaks:  English

Year of Call: 2012 - British Columbia

Primary phone: +1 604-891-2782

Fax: +1 604-683-3558


Download vCard

Primary office:  Vancouver

Mark S. Wilke, PhD

Dr. Mark Wilke is a partner based out of Vancouver, Canada, practising in the firm's global Intellectual Property and Life Sciences groups.

His practice focuses on international patent prosecution and strategic patent portfolio counseling across a broad range of industries, including pharmaceuticals, biotechnology, agriculture, and cleantech, with an emphasis on patenting innovative technologies in the areas of molecular biology, immunology, biochemistry, chemistry, chemical engineering, and medical devices.

Prior to his legal career, Mark completed a doctorate at the University of British Columbia, where he investigated the regulation of antibiotic resistance in pathogenic superbugs using X-ray crystallography and nuclear magnetic resonance.

Mark is a registered patent agent in both Canada and the United States.

Career & Recognition

Filter timeline:
  • 2013

    • Career
      December 2013
      Patent Agent, USA
    • Career
      September 2013
      Patent Agent, Canada
    • Career
      April 2013
      Trademark Agent, Canada
  • 2012

    • Qualifications (Year of Call/Admission, etc.)
      Year of Call, British Columbia
  • 2011

    • Education
      University of British Columbia, JD
  • 2008

    • Education
      University of British Columbia, PhD, Biochemistry
  • 2002

    • Education
      University of Guelph, B.Sc., Biochemistry


  • Canadian Bar Association
  • Intellectual Property Institute of Canada (IPIC)

Wilke, MS et al., "Patenting across three jurisdictions", Intellectual Property Magazine, April 2020, pages 37-38.

Wilke MS, Prohibiting Medical Method Patents: A Criticism of the Status Quo, 2011, C.J.L.T. 9(2), 2009.

Wilke MS, Heller M, Creagh L, Haynes C, McIntosh L, Poole K, Strynadka NC (2008) The crystal structure of MexR from Pseudomonas aeruginosa in complex with its anti-repressor ArmR. Proc Natl Acad Sci USA 105, 14832-37.

Daigle DM, Cao L, Fraud S, Wilke MS, Pacey A, Klinoski R, Strynadka NC, Dean CR, and Poole K. (2007) A Protein Modulator of Multidrug Efflux Gene Expression in Pseudomonas aeruginosa. J Bacteriol 189, 5441-51.

Wilke MS, Lovering AL, Strynadka NC (2005) Beta-lactam antibiotic resistance: a current structural perspective. Curr Opin Microbiol 8, 525-33.

Wilke MS, Hills TL, Zhang HZ, Chambers HF, Strynadka NC (2004) Crystal structures of the apo and penicillin-acylated forms of the BlaR1 beta-lactam sensor of Staphylococcus aureus. J Biol Chem 279, 47278-87.

Bateman KP, Baker J, Wilke M, Lee J, Leriche T, Seto C, Day S, et al. (2004) Detection of covalent adducts to cytochrome P450 3A4 using liquid chromatography mass spectrometry. Chem Res Toxicol 17, 1356-61.